Furthermore, evidence demonstrates that the Akt/cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) pathway, which induces the upregulation of BDNF, is a promising therapeutic target in neurodegenerative diseases including AD [40]. Here, AKT1 is linked to neurodegenerative disease.